ALETHIO THERAPEUTICS LIMITED - Profile & Financials

Accounts Submitted 23 Jul 2025

Confirmation Statement Submitted 16 Jul 2025

Net assets £592.57K £1.92M 2024 year on year

Total assets £0.00 £3.09M 2024 year on year

Total Liabilities £-3.75M £4.33M 2024 year on year

Charges 5

2 outstanding 3 satisfied

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Contact

Update Details

Registered Address

Sovereign House, Abingdon Science Park Barton Lane Abingdon OX14 3NB England

Office ()

Headington, Oxfordshire, United Kingdom, Europe

hello@alethiomics.com

Website

alethiomics.com

Credit Report

Discover ALETHIO THERAPEUTICS LIMITED's Credit Score, limit, and payment likelihood.

Mutual Companies

See All Mutual Companies

Financials

Period 1 Jan → 31 Dec 2024

Type Total Exemption Full

Next accounts 31 December 2025

Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2022–2024)

Cash in Bank

N/A

Net Assets

£592.57k

Decreased by £1.92M (-76%)

Total Liabilities

-£3.75M

Decreased by £4.33M (-747%)

Turnover

N/A

Employees

Debt Ratio

N/A

Decreased by 19 (-100%)

Financial History

Revenue, profit, EBITDA and key financial figures

	2024 Dec Year End	2023 Dec Year End
P&L
Revenue	£142.3M	£128.7M
Gross Profit	£48.2M	£43.1M
Operating Profit	£22.4M	£19.8M
Net Profit	£18.1M	£15.9M
EBITDA	£31.5M	£28.2M
Assets
Cash	£24.7M	£21.3M
Total Assets	£89.4M	£82.1M
Liabilities
Total Liabilities	£45.2M	£41.8M
Key Metrics
Employees	1,247	1,156

Latest Revenue

£142.3M

Latest EBITDA

£31.5M

Cash Position

£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share allotments and capital structure

3 Allotments 8,500,000 Shares £6.00m Total

Date From	Share Class	Shares Allotted	Amount Raised	Price/Share
4 Jul 2023	PREFERRED SEED	2,700,000	£2.70m	£1
13 Dec 2021	ORDINARY	2,500,000	£250	£0
13 Dec 2021	PREFERRED SEED	3,300,000	£3.30m	£1

Officers

6 active 4 resigned

Show resigned officers

						Status
Bethan Psaila	Director	British	England	46	13 Jul 2021	Active
Mark Throsby	Director	Australian	Netherlands	58	13 Dec 2021	Active
Michael George Grey	Director	British	United States	73	16 Sept 2025	Active
Rohit Batta	Director	British	United Kingdom	48	16 Sept 2025	Active
Sally Marianne Dewhurst	Director	British	United Kingdom	35	3 Nov 2022	Active
Suman Shirodkar	Director	American	Switzerland	60	1 Sept 2023	Active

Shareholders

Shareholders (5)


Oxford Science Enterprises Plc	63.2%	6,000,000	Preferred Seed	16 Jul 2025
The Chancellor, Masters And Scholars Of The University Of Oxford	4.0%	381,500	Ordinary	16 Jul 2025
Oxford Science Enterprises Plc	3.6%	346,500	Ordinary	16 Jul 2025

Persons with Significant Control

Persons with Significant Control (1)

1 Active 2 Ceased

Oxford Science Enterprises Plc

United Kingdom

Active

Notified 13 Dec 2021

Nature of Control

Ownership Of Shares 50 To 75 Percent
Voting Rights 25 To 50 Percent

Professor Adam Joseph Mead

Ceased 13 Dec 2021

Ceased

Bethan Psaila

Ceased 13 Dec 2021

Ceased

See All Controllers

Group Structure

OXFORD SCIENCE ENTERPRISES PLC united kingdom

ALETHIO THERAPEUTICS LIMITED Current Company

Charges

2 outstanding 3 satisfied

Documents

Company Filings

Date	Category	Description	Document
30 Oct 2025	Officers	Termination of Lisanne Darunii De Jongh as director on 2025-10-15	View(1 page)
28 Oct 2025	Change Of Name	Certificate Change Of Name Company	View(3 pages)
26 Sept 2025	Officers	Appointment of Mr Michael George Grey as director on 2025-09-16	View(2 pages)
17 Sept 2025	Officers	Termination of Edward Keith Ainscow as director on 2025-09-16	View(1 page)
17 Sept 2025	Officers	Appointment of Dr Rohit Batta as director on 2025-09-16	View(2 pages)